505 related articles for article (PubMed ID: 31164885)
21. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.
Thielen AJF; van Baarsen IM; Jongsma ML; Zeerleder S; Spaapen RM; Wouters D
J Immunol Methods; 2018 May; 456():15-22. PubMed ID: 29447841
[TBL] [Abstract][Full Text] [Related]
22. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
[TBL] [Abstract][Full Text] [Related]
23. Expression and modulation of RPE cell membrane complement regulatory proteins.
Yang P; Tyrrell J; Han I; Jaffe GJ
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3473-81. PubMed ID: 19168900
[TBL] [Abstract][Full Text] [Related]
24. miR-132-3p regulates antibody-mediated complement-dependent cytotoxicity in colon cancer cells by directly targeting CD55.
Fan Y; Liao J; Wang Y; Wang Z; Zheng H; Wang Y
Clin Exp Immunol; 2023 Mar; 211(1):57-67. PubMed ID: 36571232
[TBL] [Abstract][Full Text] [Related]
25. The regulation of the complement system: insights from genetically-engineered mice.
Turnberg D; Botto M
Mol Immunol; 2003 Sep; 40(2-4):145-53. PubMed ID: 12914820
[TBL] [Abstract][Full Text] [Related]
26. The expression of membrane-bound complement regulatory proteins CD46, CD55 and CD59 in oral lichen planus.
Li L; Cong B; Yu X; Deng S; Liu M; Wang Y; Wang W; Gao M; Xu Y
Arch Oral Biol; 2021 Apr; 124():105064. PubMed ID: 33529836
[TBL] [Abstract][Full Text] [Related]
27. Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells.
Zhao WP; Zhu B; Duan YZ; Chen ZT
Oncol Rep; 2009 Jun; 21(6):1405-11. PubMed ID: 19424617
[TBL] [Abstract][Full Text] [Related]
28. Protective effects of different combinations of human MCP, DAF, and CD59 on complement-dependent cytolysis in NIH 3T3 cells.
Yang X; Deng J; Jiang Z; Liao DJ; Jiang H
Exp Clin Transplant; 2012 Feb; 10(1):49-54. PubMed ID: 22309420
[TBL] [Abstract][Full Text] [Related]
29. Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review).
Maio M; Brasoveanu LI; Coral S; Sigalotti L; Lamaj E; Gasparollo A; Visintin A; Altomonte M; Fonsatti E
Int J Oncol; 1998 Aug; 13(2):305-18. PubMed ID: 9664126
[TBL] [Abstract][Full Text] [Related]
30. Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.
Cinci M; Mamidi S; Li W; Fehring V; Kirschfink M
Target Oncol; 2015 Sep; 10(3):405-13. PubMed ID: 25395366
[TBL] [Abstract][Full Text] [Related]
31. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade.
Shao F; Gao Y; Wang W; He H; Xiao L; Geng X; Xia Y; Guo D; Fang J; He J; Lu Z
Nat Cancer; 2022 Oct; 3(10):1192-1210. PubMed ID: 36271172
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma.
Gelderman KA; Kuppen PJ; Bruin W; Fleuren GJ; Gorter A
Eur J Immunol; 2002 Jan; 32(1):128-35. PubMed ID: 11754353
[TBL] [Abstract][Full Text] [Related]
33. Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation.
van Beek J; van Meurs M; 't Hart BA; Brok HP; Neal JW; Chatagner A; Harris CL; Omidvar N; Morgan BP; Laman JD; Gasque P
J Immunol; 2005 Feb; 174(4):2353-65. PubMed ID: 15699172
[TBL] [Abstract][Full Text] [Related]
34. Membrane-associated proteins regulating the complement system: functions and deficiencies.
Schieren G; Hänsch GM
Int Rev Immunol; 1993; 10(1):87-101. PubMed ID: 7688019
[No Abstract] [Full Text] [Related]
35. Complement in cancer and cancer immunotherapy.
Kolev M; Towner L; Donev R
Arch Immunol Ther Exp (Warsz); 2011 Dec; 59(6):407-19. PubMed ID: 21960413
[TBL] [Abstract][Full Text] [Related]
36. Protection of xenogeneic cardiac endothelium from human complement by expression of CD59 or DAF in transgenic mice.
Byrne GW; McCurry KR; Kagan D; Quinn C; Martin MJ; Platt JL; Logan JS
Transplantation; 1995 Nov; 60(10):1149-56. PubMed ID: 7482724
[TBL] [Abstract][Full Text] [Related]
37. Altered Expression of Complement Regulatory Proteins CD35, CD46, CD55, and CD59 on Leukocyte Subsets in Individuals Suffering From Coronary Artery Disease.
Mishra N; Mohata M; Narang R; Lakshmy R; Hazarika A; Pandey RM; Das N; Luthra K
Front Immunol; 2019; 10():2072. PubMed ID: 31555286
[TBL] [Abstract][Full Text] [Related]
38. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.
Donin N; Jurianz K; Ziporen L; Schultz S; Kirschfink M; Fishelson Z
Clin Exp Immunol; 2003 Feb; 131(2):254-63. PubMed ID: 12562385
[TBL] [Abstract][Full Text] [Related]
39. [Self- and non-self recognition mechanism via the complement system].
Okada N
Nihon Rinsho; 2005 Apr; 63 Suppl 4():279-83. PubMed ID: 15861669
[No Abstract] [Full Text] [Related]
40. Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs.
Gelderman KA; Lam S; Gorter A
Expert Opin Biol Ther; 2005 Dec; 5(12):1593-601. PubMed ID: 16318423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
